Previous Close | 0.2000 |
Open | 0.0800 |
Bid | 0.0000 |
Ask | 0.2300 |
Strike | 42.50 |
Expire Date | 2024-10-18 |
Day's Range | 0.0800 - 0.2000 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
JNJ beats estimates for third-quarter earnings and sales. It lowers earnings expectations for 2024 but raises the sales guidance range.
Repare stock gains 8% as the company initiates dosing patients in its phase I study of the RP-3467 combo regimen for advanced solid tumor indications.
AZN vs. NVO: Which Stock Is the Better Value Option?